GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » Valuation Rank

Medicenna Therapeutics (TSX:MDNA) Valuation Rank


View and export this data going back to 2015. Start your Free Trial

What is Medicenna Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Medicenna Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Medicenna Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicenna Therapeutics (TSX:MDNA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » Valuation Rank
Comparable Companies
TSX:RVX TSXV:SBM XCNQ:DOSE TSXV:NRX NEOE:BMND TSXV:IBT XCNQ:MDMA XCNQ:COOL XCNQ:TELI TSXV:COV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
MDNAF:USA
Address
2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2
Website
https://www.medicenna.com
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
Executives
Albert George Beraldo Director
Chandra Panchal Director